Testing BLU-5937 for treating persistent cough in adults
Official title: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough
Run by Bellus Health Inc. - a GSK company · NCT05600777 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new medication called BLU-5937 to see if it can help adults with a long-lasting cough feel better after 24 weeks of treatment.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 825 (estimated) |
| Sponsor | Bellus Health Inc. - a GSK company Industry-sponsored |
| Locations | 100 sites (Gulf Shores, Alabama and 99 other locations) |
| Trial ID | NCT05600777 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with refractory chronic cough lasting at least one year who can provide informed consent.
✕Probably not a fit
Patients with chronic obstructive pulmonary disease (COPD), bronchiectasis, or other specified respiratory conditions will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of BLU-5937 in adults suffering from refractory chronic cough (RCC). The primary goal is to measure the impact of BLU-5937 on the frequency of coughing over a 24-hour period after 24 weeks of treatment. Participants will be randomly assigned to receive either the active medication or a placebo. The study aims to provide insights into a potential new treatment option for individuals with this challenging condition.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce cough frequency and improve the quality of life for patients with refractory chronic cough.
How similar studies have gone: Other studies have explored treatments for chronic cough, but the specific approach with BLU-5937 is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Capable of giving signed informed consent * Refractory chronic cough (including unexplained chronic cough) for at least one year * Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose Exclusion Criteria: * Current smoker/vaper (all forms of smoking and inhaled substances, including , cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history * Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, idiopathic pulmonary fibrosis or uncontrolled asthma * Respiratory tract infection within 4 weeks before screening * Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening * History of malignancy in the last 5 years * History of alcohol or drug abuse within the last 3 years * Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus. * Previous participation in a BLU-5937 trial
Where it's running
-
G & L Research, LLC
Gulf Shores, Alabama, United States Recruiting -
California Allergy & Asthma Medical Group Inc.
Los Angeles, California, United States Recruiting -
Southern California Institute For Respiratory Diseases, Inc.
Los Angeles, California, United States Recruiting -
Paradigm Clinical Research Centers, Inc.
Redding, California, United States Recruiting -
Precision Research Institute, LLC
San Diego, California, United States Recruiting -
Allergy & Asthma Associates of Santa Clara Valley
San Jose, California, United States Recruiting
Show 44 more locations
-
Colorado Allergy and Asthma Centers, PC
Denver, Colorado, United States Recruiting -
Clinical Site Partners, LLC d/b/a CSP Leesburg
Leesburg, Florida, United States Recruiting -
Savin Medical Group LLC
Miami Lakes, Florida, United States Recruiting -
Destin Pulmonary Critical Care, PLLS.
Santa Rosa Beach, Florida, United States Recruiting -
Lenus Research & Medical Group
Sweetwater, Florida, United States Recruiting -
In-Quest Medical Research, LLC
Norcross, Georgia, United States Recruiting -
The Iowa Clinic, PC
Ankeny, Iowa, United States Recruiting -
Minnesota Lung Center
Edina, Minnesota, United States Recruiting -
Mayo Clinic - Rochester
Rochester, Minnesota, United States Recruiting -
Minnesota Lung Center
Woodbury, Minnesota, United States Recruiting -
The Clinical Research Center, LLC
Saint Louis, Missouri, United States Recruiting -
Creighton University
Omaha, Nebraska, United States Recruiting -
ActivMed Practices & Research, LLC
Portsmouth, New Hampshire, United States Recruiting -
PMG Research of Charlotte, LLC
Charlotte, North Carolina, United States Recruiting -
Clinical Research of Gastonia
Gastonia, North Carolina, United States Recruiting -
Accellacare
Winston-Salem, North Carolina, United States Recruiting -
Optimed Research, LTD
Columbus, Ohio, United States Recruiting -
Pharmacorp Clinical Trials, Inc.
Charleston, South Carolina, United States Recruiting -
Clinical Trials Center of Middle Tennessee
Franklin, Tennessee, United States Recruiting -
Houston Pulmonary, Sleep, Allergy and Asthma Associates
Cypress, Texas, United States Recruiting -
Quality Assurance Research Center
San Antonio, Texas, United States Recruiting -
AMR Norfolk, Formerly Tidewater Associates, an AMR Company
Norfolk, Virginia, United States Recruiting -
Northside Health
Coffs Harbour, New South Wales, Australia Recruiting -
Lung Research QLD Pty Ltd
Chermside, Queensland, Australia Recruiting -
The Prince Charles Hospital
Chermside, Queensland, Australia Recruiting -
Royal Adelaide Hospital
Adelaide, South Australia, Australia Recruiting -
Institute for Respiratory Health Inc
Nedlands, Western Australia, Australia Recruiting -
TrialsWest
Spearwood, Western Australia, Australia Recruiting -
MUDr. I. Cierna Peterova s.r.o.
Brandýs Nad Labem, Czechia Recruiting -
Fakultni nemocnice Brno
Brno, Czechia Recruiting -
MUDr. Otakar Hokynar plicni ordinace
Kralupy Nad Vltavou, Czechia Recruiting -
Plicni ambulance - MUDr. Ilona Pavlisova
Miroslav, Czechia Recruiting -
DAWON spol. s.r.o.
Prague, Czechia Recruiting -
MUDr. Jaroslav Mares - TBC a respir. nemoci
Strakonice, Czechia Recruiting -
Thoraxklinik Heidelberg gGmbH
Heidelberg, Baden Wuerttemberg, Germany Recruiting -
Pneumologische Praxis Pasing
Muenchen, Bayern, Germany Recruiting -
Lungenzentrum Darmstadt
Darmstadt, Hessen, Germany Recruiting -
Studienzentrum Maingau
Frankfurt am main, Hessen, Germany Recruiting -
Klinikum der Johann Wolfgang Goethe-Universitaet
Frankfurt, Hessen, Germany Recruiting -
Medaimun GmbH
Frankfurt, Hessen, Germany Recruiting -
Zentrum fuer ambulante pneumologische Forschung Marburg GbR
Marburg, Hessen, Germany Recruiting -
Ballenberger Freytag Wenisch Institut für klinische Forschung
Neu Isenburg, Hessen, Germany Recruiting -
Pneumologicum Halle
Halle, Sachsen Anhalt, Germany Recruiting -
Pneumologisches Forschungsinstitut Hohegeest GbR
Geesthacht, Schleswig Holstein, Germany Recruiting
+50 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: US GSK Clinical Trials call Center
- Email: GSKClinicalSupportHD@gsk.com
- Phone: 877-379-3718
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Nalbuphine ER for chronic cough in people with RCC
This study tests whether extended-release nalbuphine helps people with unexplained, long-standing cough that hasn’t improved with other treatments.
-
BLU-5937 for Refractory Chronic Cough: 24-Week Test in Adults (China Extension)
This study tests whether BLU-5937 can reduce 24-hour cough frequency in adults with refractory or unexplained chronic cough.
-
Cough Management app for refractory or unexplained chronic cough
This trial will see if using a smartphone Cough Management program plus a smartwatch for four weeks lowers coughing and improves quality of life in adults 21–80 with refractory or unexplained chronic cough.
-
Behavioral Cough Suppression Therapy with or without an inhaled aid for refractory chronic cough
This study tests whether adding an inhaled substance to behavioral cough suppression helps people with persistent chronic cough see if it works better than behavior therapy alone.
-
Testing Duloxetine and Amitriptyline for Chronic Cough Relief
This study is testing if two medications, Duloxetine and Amitriptyline, can help people with a stubborn chronic cough feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.